CEL-SCI Corporation

CVM | AMEX

Price Alert Chart Builder DCF Calculator

$1.66

-$0.01 (-0.60%)

Sep 22, 2026, 10:58 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.60%

(1D)

Rating

Updated: Aug 31, 2026

23.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $11.41M

1D Range

1.66 1.70

52W Range

0.89 10.83

Valuation (TTM)

PE -0.66

PB 0.00

EV/EBITDA -75.05

Valuation (NTM)

Forward PE N/A

Forward PEG -0.01

Price Target N/A

Cash Flow

FCF Yield -143.4%

SBC Adj. FCF Yield -158.7%

SBC Impact -10.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y 0.0% | 50.0%

Dil EPS 3Y | 5Y 74.3% | 38.1%

FCF 3Y | 5Y 6.6% | 5.6%

Returns

ROA -106.3%

ROE -202.1%

ROIC -117.4%

Financial Health

Net Debt

$1.37B

Current Ratio 1.48

Interest Coverage -50.19

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is curren...

Sector Healthcare

Industry Biotechnology

Employees 43

IPO Date Dec 7, 1983

Website cel-sci.com

Fiscal Year October - September

Full Company Profile

Latest News

No news articles available yet.